LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, ...
13d
Curiox Biosystems Signs Master Software License Agreement for Enterprise-Scale Pluto Code Deployment
WOBURN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Curiox Biosystems today announced the signing of a Master Software License Agreement with a major global pharmaceutical organization for the ...
Barman PhD BEDFORD, MA, UNITED STATES, April 29, 2026 /EINPresswire.com/ — Bedford, MA-based Integral BioSystems will present data on OcuHeal-UV400+, an innovative, UV-blocking, antioxidant eyedrop at ...
BEDFORD, MA, UNITED STATES, April 29, 2026 /EINPresswire.com/ — Bedford, MA-based Integral BioSystems will present at the Annual ARVO Convention to be held May 3-May 7, 2026 at Denver, Colorado. The ...
T2 Biosystems makes medical diagnostic testing equipment. The company reported a likely 60% in revenue in a preliminary third-quarter earnings report. T2 Biosystems also did a negative stock split to ...
"A device is only as good as the system around it," said Samara Barend, CEO of AION Biosystems. "Olio provides exactly the coordination infrastructure that turns our data into action. A patient goes ...
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine, today ...
Cell counting is a critical step in biomedical research applications, clinical diagnostics, and cell therapy administration. Compared to tedious and time-consuming manual cell counting, the Corning ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, today announced that it has received a $72.75 ...
White Brook Capital Partners, an investment management firm, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter indicated that the first quarter ...
Initiating Rapid Micro Biosystems at 'buy' with $4.60 fair value, driven by strong growth potential in automated microbial quality control market. Growth Direct platform offers clear advantages over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results